<DOC>
	<DOCNO>NCT01848041</DOCNO>
	<brief_summary>This exploratory , proof concept study evaluate safety efficacy RVL-1201 dose twice daily 14 day compare placebo ( vehicle ) control patient ptosis .</brief_summary>
	<brief_title>Safety Efficacy Study RVL-1201 Acquired Blepharoptosis</brief_title>
	<detailed_description>This exploratory , proof-of-concept study . The objective include establish efficacy duration effect daily ( QD ) twice daily ( BID ) administration RVL-1201 safety profile follow 14 day treatment 72 subject ( 24 per arm ) acquire blepharoptosis . Efficacy assess treatment visit Humphrey Visual Field 36-point ptosis protocol test , photographic measurement marginal reflex distance , palpebral fissure distance contrast sensitivity study eye Visual Acuity assessment eye . Safety assessment include slit lamp examination/corneal fluorescein staining , pupil size measurement , ophthalmoscopy/ fundus examination , tonometry , visual acuity ; urine pregnancy test ( woman childbearing potential ) , vital sign ( Heart Rate/Blood Pressure ) ; collection adverse event . Subject rating study medication comfort assessment ongoing tolerability also obtain . Primary efficacy endpoint mean increase baseline point see HVF 36-point ptosis protocol test various timepoints accord hierarchical analysis . Analysis exploratory endpoint provide characterization efficacy duration effect RVL-1201 variety efficacy measure , well potential additional effect BID QD dose safety profile BID administration RVL-1201 . Exploratory endpoint analyze regimen placebo regimens include : - The change baseline HVF , MRD , PFD , VA , CS . - The change baseline BP/HR</detailed_description>
	<mesh_term>Blepharoptosis</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Adult male female subject 18 year age old . 2 . Presence follow Screening : 1 . Loss HVF 36point ptosis protocol test ≥ 8 point point see 10° fixation superior visual field ; AND 2 . Marginal reflex distance ( MRD ) , distance central pupillary light reflex upper lid margin , ≤ 2.5 mm eye Inclusion Criterion # 2a ; AND 3 . Corrected Snellen visual acuity ( VA ) 20/40 good ( refraction must within 6 month Visit 1 ) eye Inclusion Criteria # 2a # 2b . 3 . No contraindication treatment eye specify Exclusion Criteria # 114 . 4 . Female subject must 1year postmenopausal , surgically sterilize , woman childbearing potential negative urine pregnancy test Visit 1 . Women childbearing potential must use acceptable form contraception throughout study . 5 . Provide informed consent prior undergoing studyrelated procedure . In either eye : 1 . Congenital ptosis 2 . Pseudoptosis 3 . Horner syndrome 4 . Marcus Gunn jawwinking syndrome 5 . Myasthenia gravis 6 . Mechanical ptosis , include ptosis due orbital lid tumor , cicatricial process affect movement upper lid , enophthalmos 7 . Dermatochalasis sole cause sign ptosis 8 . Previous ptosis surgery 9 . Lid position affect lid conjunctival scar 10 . Current use prescribe dry eye medication punctal plug ; artificial tear allow 11 . Visual field loss cause ptosis 12 . Inability fixate central fixation target HVF 13 . Primary openangle glaucoma ocular hypertension , intraocular pressure ( IOP ) &gt; 24 mm Hg , current use/use within 1 month prior Visit 1 antiglaucoma medication . 14 . History closed/narrow angle glaucoma ( unless patent peripheral iridotomy perform &gt; 3 month prior Visit 1 IOP &lt; 20 mm Hg ) normaltension glaucoma 15 . Use overthecounter vasoconstrictor/decongestant eye medication ( eg , Visine® L.R.® ) αadrenergic agonist ( include OTC product ) time study 16 . Contact lens wear study period General : 17 . Resting heart rate ( HR ) outside normal range ( 60 100 beat per minute ) 18 . Hypertension diastolic blood pressure ( BP ) &gt; 105 mm Hg 19 . Use monoamine oxidase inhibitor ( MAOIs ; eg , isocarboxazid , phenelzine , tranylcypromine ) within 14 day prior Visit 1 study 20 . Use beta blocker ( eg , propranolol , metoprolol , labetalol ) within 14 day prior Visit 1 study 21 . Use maprotiline , selective serotonin reuptake inhibitor ( [ SSRIs ] eg , citalopram , escitalopram , paroxetine , fluoxetine , fluvoxamine , sertraline ) tricyclic antidepressant ( eg , amitriptyline , doxepin , nortriptyline , amoxapine , clomipramine , desipramine , imipramine , protriptyline , trimipramine ) time study 22 . A history myocardial infarction , angina , arrhythmia , irregular pulse 23 . Advanced arteriosclerotic disease 24 . History thyroid disease 25 . Insulindependent diabetes diabetes require oral hypoglycemic drug ; dietcontrolled diabetes allow 26 . Pregnancy lactation 27 . Diagnosed benign prostatic hypertrophy require medicinal therapy . 28 . History contact systemic allergic reaction oxymetazoline sympathomimetic drug ( eg , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine , fepradinol , methoxamine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Blepharoptosis</keyword>
	<keyword>Ptosis</keyword>
</DOC>